Table 1 The demographic, clinical and pathological features of the patients with pMN, FSGS and MCD
From: Complement activation products in the circulation and urine of primary membranous nephropathy
Parameters | PMN (N = 134) | FSGS (N = 72) | MCD (N = 18) | P |
|---|---|---|---|---|
Gender (male), n (%) | 79 (59.0) | 48 (66.7) | 8 (44.4) | 0.201 |
Age (years) | 52.0 (18.0–76.0) | 28.5 (13.0–84.0) | 55.5 (15.0–81.0) | < 0.001 |
Nephrotic syndrome | 79 (59.0%) | Â | Â | Â |
Albumin (g/L) | 26.4 (15.1–44.7) | 19.9 (12.0–43.9) | 24.0 (14.5–39.4) | < 0.001 |
Serum creatinine (μmol/L) | 63.1 (33.4–119.6) | 94.0 (43.0–931.0) | 63.3 (42.5–164.2) | < 0.001 |
eGFR (ml/min/1.73m2) | 120.7 (56.6–248.5) | 82.0 (4.7–281.6) | 108.7 (30.4–266.1) | < 0.001 |
Proteinuria (g/24 h), median (range) | 4.3 (0.2–20.9) | 7.6 (0.8–27.9) | 3.8 (0.02–18.2) | < 0.001 |
Anti-PLA2R antibody positivity, n (%) | 91 (67.9%) | – | – | – |
Anti-PLA2R antibody levels (+) (RU/ml) | 83.9 (22.5–384.9) | – | – | – |
Anti-PLA2R antibody levels (RU/ml) | 38.4 (0.0–384.9) | – | – | – |
IgG staining, n (%) | 130 (97.0) | 1 (1.4) | 3 (16.7) | < 0.001 |
IgA staining, n (%) | 27 (20.2) | 6 (8.3) | 1 (5.6) | 0.045 |
IgM staining, n (%) | 42 (31.3) | 42 (58.3) | 9 (50.0) | 0.001 |
C3-staining, n (%) | 116 (86.6) | 14 (19.4) | 5 (27.8) | < 0.001 |
C1q-staining, n (%) | 31 (23.1) | 3 (4.2) | 0 (0.0) | < 0.001 |
Stage I glomerular lesion, n (%) | 59 (44.0%) | – | – | – |
Stage II glomerular lesion, n (%) | 61 (45.5%) | – | – | – |
Stage III glomerular lesion, n (%) | 14 (10.5%) | – | – | – |